Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Merestinib in NSCLC with MET Exon 14 Mutations and NTRK Rearranged Solid Tumors
NCT02920996Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2016
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial of merestinib in non-small cell lung cancer (NSCLC) and solid tumor (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Response Rate. Started Nov 2016; status: terminated.
02
Drugs
merestinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT02920996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920996.